Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.13 (
protein kinase C
)
49,245
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A novel protein kinase (named
PKD
) with an NH2-terminal region containing two cysteine-rich motifs has been expressed in COS-7 cells and identified as a receptor for phorbol esters. COS-7 cells transfected with a
PKD
cDNA construct (pcDNA3-
PKD
) exhibit a marked (4.8-fold) increase in [3H]phorbol 12,13-dibutyrate binding. An antiserum raised against the COOH-terminal 15 amino acids of
PKD
specifically recognized a single 110-kDa band in
PKD
-transfected cells.
PKD
prepared by elution from immunoprecipitates with the immunizing peptide efficiently phosphorylated the synthetic peptide syntide-2. The enzyme only poorly phosphorylated a variant syntide-2 where arginine 4 has been replaced by an alanine. The addition of [3H]phorbol 12,13-dibutyrate, 1-oleoyl-2-acetylglycerol, or 1,2-dioctanoyl-sn-glycerol in the presence of dioleoylphosphatidylserine stimulated the syntide-2 kinase activity of
PKD
in a synergistic fashion (4-6-fold). Furthermore, the autophosphorylation of
PKD
was strikingly stimulated by the same lipid activators (14-24-fold). Similar properties were found with
PKD
isolated from mouse lung. The substrate specificity of
PKD
is different from that of previously identified members of the
protein kinase C
family since it does not efficiently phosphorylate histone III-S, protamine sulfate, or a synthetic peptide based upon the conserved pseudosubstrate region of the
protein kinase C
family. Taken together, these data unambiguously establish
PKD
as a phorbol ester receptor and as a novel phospholipid/diacylglycerol-stimulated protein kinase.
...
PMID:Expression and characterization of PKD, a phorbol ester and diacylglycerol-stimulated serine protein kinase. 783 15
A serine/threonine protein kinase that binds phorbol esters and diacylglycerol (named protein kinase D,
PKD
) has been identified.
PKD
contains membrane localization signals and a cysteine-rich repeat sequence homologous to that seen in the regulatory domain of
protein kinase C
(
PKC
). A bacterially expressed N-terminal domain of
PKD
exhibited high-affinity phorbol ester binding activity (Kd = 35 nM). The diacylglycerol analog 1-oleoyl-2-acetylglycerol inhibited phorbol ester binding in a dose-dependent manner. The catalytic domain of
PKD
contains all characteristic sequence motifs of serine protein kinases but shows only a low degree of sequence similarity to PKCs. The highest identity is with the catalytic domain of myosin light-chain kinase from Dictyostelium (41%). The bacterially expressed catalytic domain of
PKD
efficiently phosphorylated the exogenous peptide substrate syntide 2 in serine but did not catalyze significant phosphorylation of a variety of other substrates used by PKCs and other major second messenger regulated kinases.
PKD
may be an unusual component in the transduction of diacylglycerol and phorbol ester signals.
...
PMID:Molecular cloning and characterization of protein kinase D: a target for diacylglycerol and phorbol esters with a distinctive catalytic domain. 807 25
A novel serine/threonine protein kinase regulated by phorbol esters and diacylglycerol (named
PKD
) has been identified.
PKD
contains a cysteine-rich repeat sequence homologous to that seen in the regulatory domain of
protein kinase C
(
PKC
). A bacterially expressed NH2-terminal domain of
PKD
exhibited high affinity phorbol ester binding activity (Kd = 35 nM). Expression of
PKD
cDNA in COS cells conferred increased phorbol ester binding to intact cells. The catalytic domain of
PKD
contains all characteristic sequence motifs of serine protein kinases but shows only a low degree of sequence similarity to PKCs. The bacterially expressed catalytic domain of
PKD
efficiently phosphorylated the exogenous peptide substrate syntide-2 in serine but did not catalyse significant phosphorylation of a variety of other substrates utilised by PKCs and other major second messenger regulated kinases.
PKD
expressed in COS cells showed syntide-2 kinase activity that was stimulated by phorbol esters in the presence of phospholipids. We propose that
PKD
may be a novel component in the transduction of diacylglycerol and phorbol ester signals.
...
PMID:Protein kinase D (PKD): a novel target for diacylglycerol and phorbol esters. 853 23
Members of the
protein kinase C
(
PKC
) family of serine/threonine kinases are thought to play critical roles in the regulation of cellular differentiation and proliferation in many cell types. An additional member of the
PKC
family was identified through human expressed sequence tag (EST) database search and its full length cDNA was isolated. Sequence analysis revealed that the predicted translation product was composed of 890 amino acid residues and that the protein has 77.3% similarity to human
PKC
mu (PKCmu) and 77. 4% similarity to mouse
PKD
(the mouse homolog of PKCmu). We designated the new member as
protein kinase C
nu (PKCnu). The PKCnu messenger RNA was ubiquitously expressed in various tissues when analyzed by Northern blots and reverse transcriptase-coupled polymerase chain reaction (PCR) analyses. The chromosomal location of the gene was determined between markers WI-9798 and D2S177 on chromosome 2p21 region by PCR-based methods with both a human/rodent monochromosomal hybrid cell panel and a radiation hybrid mapping panel.
...
PMID:PKCnu, a new member of the protein kinase C family, composes a fourth subfamily with PKCmu. 1023 60
The clinical, pathophysiological and genetic features of some of the paroxysmal movement disorders are reviewed. Paroxysmal kinesigenic choreoathetosis/dyskinesias (
PKC
/
PKD
) is a condition in which brief and frequent dyskinetic attacks are provoked by sudden movement.
PKC
is more common in men and can be idiopathic (commonly familial) or due to a variety of causes. The pathophysiology of
PKC
is uncertain but it could be an ion-channel disorder. Antiepileptic drugs particularly carbamazepine are very helpful in a large proportion of cases. Paroxysmal exercise induced dystonia (PED) is a rare disorder manifesting as episodes of dystonia mostly affecting the feet induced by continuous exercise like walking or running. Although the initial cases were familial, there is a higher proportion of sporadic cases. The pathophysiology of PED is unknown and antiepileptic drugs are generally unhelpful. In paroxysmal dystonic choreoathetosis/non-kinesigenic dyskinesias (PDC/PNKD) the attacks are of long duration and induced by variety of factors including coffee, tea, alcohol and fatigue but not by sudden movement. PDC can be idiopathic (familial or sporadic) or symptomatic due to a variety of causes. The gene for familial PDC has been linked in 2 families to chromosome 2 q close to a cluster of ion channel genes again suggesting that this disorder may also be a channelopathy. Other paroxysmal disorders include paroxysmal nocturnal dyskinesia, a form of frontal lobe epilepsy in some cases which may be familial with autosomal dominant inheritance (ADNFLE). The gene for ADNFLE in one family has been found to be a mutation in the neuronal acetylcholine receptor gene (CHRNA4) on chromosome 20q. Tonic spasms in multiple sclerosis and Sandiffers syndrome producing intermittent torticollis in infants and children are other paroxysmal movement disorders.
...
PMID:The paroxysmal dyskinesias. 1032 9
In Rat-1 fibroblasts epidermal growth factor (EGF), but not platelet-derived growth factor (PDGF) stimulates the activity of the c-Jun N-terminal kinase (JNK). Moreover, PDGF induced suppression of EGF-mediated JNK activation, apparently through
protein kinase C
(
PKC
) activation. Further analysis revealed that
PKD
was specifically activated by PDGF but not EGF in Rat-1 cells. In SF126 glioblastoma cells, however, EGF and PDGF synergistically activated JNK, while neither PDGF nor EGF stimulated
PKD
activity. In this cell line, overexpression of
PKD
blocked EGF- and PDGF-induced JNK activation. Mutational analysis further revealed that the EGFR mutant (T654/669E) was incapable of activating JNK and provided evidence that
PKD
-mediated dual phosphorylation of these critical threonine residues leads to suppression of EGF-induced JNK activation. Our results establish a novel crosstalk mechanism which allows signal integration and definition in cells with many different RTKs.
...
PMID:Cell-type specific phosphorylation of threonines T654 and T669 by PKD defines the signal capacity of the EGF receptor. 1052 1
Protein kinase D (
PKD
/PKCmu) immunoprecipitated from COS-7 cells transiently transfected with a constitutively active alpha subunit of G(q) (Galpha(q)Q209L) exhibited a marked increase in basal activity, which was not further enhanced by treatment of the cells with phorbol 12,13-dibutyrate. In contrast, transient transfection of COS-7 cells with activated Galpha(12)Q229L or Galpha(13)Q226L neither promoted
PKD
activation nor interfered with the increase of
PKD
activity induced by phorbol 12,13-dibutyrate. The addition of aluminum fluoride to cells co-transfected with
PKD
and wild type Galpha(q) induced a marked increase in
PKD
activity, which was comparable with that induced by expression of Galpha(q)Q209L. Treatment with the protein kinase C inhibitor GF I or Ro 31-8220 prevented the increase in
PKD
activity induced by aluminum fluoride. Expression of a COOH-terminal fragment of Galpha(q) that acts in a dominant negative fashion attenuated
PKD
activation in response to agonist stimulation of bombesin receptor.
PKD
activation in response to either Galpha(q) or bombesin was completely prevented by mutation of Ser(744) and Ser(748) to Ala in the kinase activation loop of
PKD
. Our results show that Galpha(q) activation is sufficient to stimulate sustained
PKD
activation via
protein kinase C
and indicate that the endogenous Galpha(q) mediates
PKD
activation in response to acute bombesin receptor stimulation.
...
PMID:Activation of protein kinase D by signaling through the alpha subunit of the heterotrimeric G protein G(q). 1063 21
Activation of the serine/threonine kinase, protein kinase D (
PKD
/
PKC
mu) via a phorbol ester/
PKC
-dependent pathway involves phosphorylation events. The present study identifies five in vivo phosphorylation sites by mass spectrometry, and the role of four of them was investigated by site-directed mutagenesis. Four sites are autophosphorylation sites, the first of which (Ser(916)) is located in the C terminus; its phosphorylation modifies the conformation of the kinase and influences duration of kinase activation but is not required for phorbol ester-mediated activation of
PKD
. The second autophosphorylation site (Ser(203)) lies in that region of the regulatory domain, which in
PKC
mu interacts with 14-3-3tau. The last two autophosphorylation sites (Ser(744) and Ser(748)) are located in the activation loop but are only phosphorylated in the isolated
PKD
-catalytic domain and not in the full-length
PKD
; they may affect enzyme catalysis but are not involved in the activation of wild-type
PKD
by phorbol ester. We also present evidence for proteolytic activation of
PKD
. The fifth site (Ser(255)) is transphosphorylated downstream of a
PKC
-dependent pathway after in vivo stimulation with phorbol ester. In vivo phorbol ester stimulation of an S255E mutant no longer requires
PKC
-mediated events. In conclusion, our results show that
PKD
is a multisite phosphorylated enzyme and suggest that its phosphorylation may be an intricate process that regulates its biological functions in very distinct ways.
...
PMID:Regulation of protein kinase D by multisite phosphorylation. Identification of phosphorylation sites by mass spectrometry and characterization by site-directed mutagenesis. 1086 18
We have isolated the full-length cDNA of a novel human serine threonine protein kinase gene. The deduced protein sequence contains two cysteine-rich motifs at the N terminus, a pleckstrin homology domain, and a catalytic domain containing all the characteristic sequence motifs of serine protein kinases. It exhibits the strongest homology to the serine threonine protein kinases
PKD
/PKCmicro and PKCnu, particularly in the duplex zinc finger-like cysteine-rich motif, in the pleckstrin homology domain and in the protein kinase domain. In contrast, it shows only a low degree of sequence similarity to other members of the
PKC
family. Therefore, the new protein has been termed protein kinase D2 (PKD2). The mRNA of PKD2 is widely expressed in human and murine tissues. It encodes a protein with a molecular mass of 105 kDa in SDS-polyacrylamide gel electrophoresis, which is expressed in various human cell lines, including HL60 cells, which do not express PKCmicro. In vivo phorbol ester binding studies demonstrated a concentration-dependent binding of [(3)H]phorbol 12,13-dibutyrate to PKD2. The addition of phorbol 12,13-dibutyrate in the presence of dioleoylphosphatidylserine stimulated the autophosphorylation of PKD2 in a synergistic fashion. Phorbol esters also stimulated autophosphorylation of PKD2 in intact cells. PKD2 activated by phorbol esters efficiently phosphorylated the exogenous substrate histone H1. In addition, we could identify the C-terminal Ser(876) residue as an in vivo phosphorylation site within PKD2. Phosphorylation of Ser(876) of PKD2 correlated with the activation status of the kinase. Finally, gastrin was found to be a physiological activator of PKD2 in human AGS-B cells stably transfected with the CCK(B)/gastrin receptor. Thus, PKD2 is a novel phorbol ester- and growth factor-stimulated protein kinase.
...
PMID:Molecular cloning and characterization of the human protein kinase D2. A novel member of the protein kinase D family of serine threonine kinases. 1106 48
Autosomal dominant polycystic kidney disease (ADPKD) is a major, inherited disorder that is characterized by the growth of large, fluid-filled cysts from the tubules and collecting ducts of affected kidneys, and by a number of extrarenal manifestations including liver and pancreatic cysts, hypertension, heart valve defects, and cerebral and aortic aneurysms. Mutations in either of 2 different genes (PKD1 or PKD2) give rise to ADPKD. Most mutations identified in affected families appear to inactivate the
PKD
genes, and accumulating evidence suggests that a 2-hit mechanism, in which the normal PKD1 or PKD2 allele is also mutated, may be required for cyst growth. The protein products of the
PKD
genes (polycystin-1 and polycystin-2) are thought to function together as part of a multiprotein membrane-spanning complex involved in cell-cell or cell-matrix interactions. Polycystin-1 and polycystin-2 can initiate signal transduction, leading to the activation of a number of downstream effectors, including heterotrimeric G-proteins,
protein kinase C
, mitogen-activated protein kinases, beta-catenin, and the AP-1 transcription factor. In addition, polycystin-2 may function in mediating calcium flux. The pathogenesis of cyst formation is currently thought to involve increased cell proliferation, fluid accumulation, and basement membrane remodeling. It now appears that cyclic adenosine monophosphate (cAMP) metabolism is a central component of cyst formation, stimulating apical chloride secretion and driving the accumulation of cyst fluid. Recent evidence has shown that ADPKD cells also have an altered responsiveness to cyclic AMP. In contrast to normal kidney cells whose cell proliferation is inhibited by cyclic AMP, ADPKD cells are stimulated to proliferate. Thus, it is likely that an alteration in polycystin function transforms the normal cellular phenotype to one that responds to elevated cyclic AMP by an increased rate of cell proliferation and that the enlarging cyst expands by an increased rate of cyclic AMP-driven fluid secretion. Cyclic AMP and growth factors, including epidermal growth factor, have complementary effects to accelerate the enlargement of ADPKD cysts, and thereby to contribute to the progression of the disease. This knowledge should facilitate the discovery of inhibitors of signal transduction cascades that can be used in the treatment of ADPKD.
...
PMID:The genetics and physiology of polycystic kidney disease. 1124 74
1
2
3
4
5
6
7
8
9
Next >>